The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Welcome back newgrange
As king H says be good if traders become investors
For £1.5mln cap one gets £900k+ revenues to he hit for 2024) and a pipeline grown from £1.mlnnto £1.5mln
Recent interims saw record H1 revenues, reduced losses, growing pipeline and a new CEO drive
Gluck
Peter promosed more events as this is increasingly important for new business
The Company's pipeline of potential new business now stands at over £1.5m (not risk weighted and excluding Biostatistics), counting only opportunities where a specific project has been discussed with a client. The Company is working hard to both convert opportunities that have progressed to proposal stage and also to refill the funnel with earlier stage opportunities. A significant number of new client contracts are now originating from both scientific conferences (such as EORTC-NCI-AACR & AACR Annual Meeting) as well as more business focused meetings
Sorry for off discussion but with the success of oncology /SAR it's well worth looking at a drug development company that uses A.I to help clients like SAR get rgrough their trials and FDA regulations which now insist that A.I and computer modelling has been done prior to trials and submission
PYC (Physiomics)
Particularly the 3rd one
Jeff Hayman, Chairman of R&Q, said: "Stephen and Lawrence both bring relevant additional experience to the Board, in particular with regards to our priorities of reducing debt and improving the efficiency and expense base of the go-forward business. As we continue to work towards completing the sale of Accredited, these appointments also support our ongoing discussions with lenders to achieve their necessary approvals."
DoseMeRx is a game-changing solution that enables customers to accelerate their precision dosing strategies with superior analytics and reporting. The guideposts of DoseMe’s ongoing investment are to improve overall clinical expertise and valuable clinical decision support to assist customers in offering the highest quality patient care.
This surge in clientele was boosted by strategic partnerships worldwide, underscoring DoseMe’s commitment to global expansion and continuous innovation to deliver advanced precision dosing.
Another great day of rises
The added bonus is that AIM company is using their A.I technology to help Sareum lead assets . There is avery good chance SAR trials will be positive as the success rate of PYC tech is very high and work with Merck, Sar etc
Net assets after sale = 80 cent (60p)15 Mar 2024 18:55
Adjusted for closing of the Sale and subsequent de-leveraging of R&Q assuming Available Net Cash Proceeds of $170 million (at the lower end of the expected range), R&Q's current estimated pro-forma financial position as at 30 June 2023 would be as follows:
Assets
$2.0 billion
Debt
$203 million
Shareholders' Equity
$356 million
Debt to Capital Ratio
36%
Group Solvency Ratio
>200%
Net Asset Value Per Common Share
80 cents